Global Patent Index - EP 1000082 A2

EP 1000082 A2 2000-05-17 - ANTIGEN BINDING FRAGMENTS, DESIGNATED 4B5, THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS

Title (en)

ANTIGEN BINDING FRAGMENTS, DESIGNATED 4B5, THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS

Title (de)

ANTIGENBINDUNGSFRAGMENTE, GENANNT 4B5, DIE SPEZIFISCH KREBSZELLEN NACHWEISEN, NUKLEOTIDE DIE FÜR DIESE FRAGMENTE KODIEREN, UND DEREN VERWENDUNG ZUR VORBEUGUNG UND ZUM NACHWEIS VON KREBS

Title (fr)

FRAGMENTS DE LIAISON ANTIGENIQUES DESIGNES PAR 4B5, QUI DETECTENT SPECIFIQUEMENT LES CELLULES CANCEREUSES, NUCLEOTIDES CODANT LESDITS FRAGMENTS ET LEUR UTILISATION POUR LA PROPHYLAXIE ET LA DETECTION DES CANCERS

Publication

EP 1000082 A2 (EN)

Application

EP 98929569 A

Priority

  • IB 9801046 W
  • US 5194597 P

Abstract (en)

[origin: WO9902545A2] The present invention relates to monoclonal antibody 4B5 and antigen binding fragments that specifically bind to the antibodies specific for GD2. Also disclosed are polynucleotide and polypeptide derivatives based on 4B5, including single chain V region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 4B5 antibody is effective in diagnosing, and/or treating neoplasias. The invention further provides methods for treating a neoplastic disease, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and lung carcinomas. Patients who are in remission as a result of traditional modes of cancer therapy can be treated with a composition of this invention in hopes of reducing the risk of recurrence. Patients can also be treated concurrently with the antibodies and traditional anti-neoplastic agents.

IPC 1-7 (main, further and additional classification)

C07H 21/00

IPC 8 full level (invention and additional information)

G01N 33/577 (2006.01); A61K 31/7088 (2006.01); A61K 38/21 (2006.01); A61K 38/22 (2006.01); A61K 39/02 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61K 47/48 (2006.01); A61K 48/00 (2006.01); A61K 51/00 (2006.01); C07K 16/00 (2006.01); C07K 16/42 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 15/09 (2006.01); G01N 33/68 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)

CPC (invention and additional information)

C07K 16/4266 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01)

Citation (search report)

See references of WO 9902545A3

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9902545 A2 19990121; WO 9902545 A3 19990401; AU 7927398 A 19990208; CA 2295375 A1 19990121; EP 1000082 A2 20000517; JP 2001509369 A 20010724; NZ 501990 A 20020927

INPADOC legal status


2005-08-17 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20050201

2001-08-29 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: VIVENTIA BIOTECH INC.

2000-05-17 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20000110

2000-05-17 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A2

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE